linjc16/ctgov huggingface dataset:
Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

Study Overview
=================
Brief Summary
-----------------
Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Detailed Description
-----------------
Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

Official Title
-----------------
Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

Conditions
-----------------
Glioblastoma Multiforme, Angiogenesis

Intervention / Treatment
-----------------
* Radiation: Chemoradiation with temozolomide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age older than 20 year old. Glioblastoma patients who will receive chemoradiation treatment. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Chemoradiation with temozolomide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response of bevacizumab therapy. | Base on the image after bevacizumab therapy (after recurrence) | 3 months after bevacizumab therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glioblastoma, Bevacizumab
A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

Official Title
-----------------
Real-World Clinical and Patient Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Conditions
-----------------
Myelofibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Primary myelofibrosis (PMF), post- Essential thrombocythemia (ET) Myelofibrosis (MF), or post- Polycythemia vera (PV) MF Treated with FEDR and initiated treatment after 16 August 2019. Received prior treatment with RUX. Had spleen assessed at time of initiation of FEDR by palpation. Able to read and speak English Willing to provide informed consent Willing to provide permission to the site to release her/his medical information to the study investigators according to the study-specific eCRF Willing to complete the baseline survey prior to first FEDR Exclusion Criteria: Past or current participant in any FEDR-related clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1<br>Participants that have discontinued RUX therapy and initiated FEDR prospectively | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage change in Total Symptom Score (TSS) assessed by Myelofibrosis Symptom Assessment Form (MFSAF) |  | At Baseline, 3 and 6 months post-FEDR initiation | 
| Absolute change in TSS assessed by MFSAF |  | At Baseline, 3 and 6 months post-FEDR initiation | 
| Proportion of participants reporting individual symptoms in TSS assessed by MFSAF |  | At Baseline, 3 and 6 months post-FEDR initiation | 
| Severity of each reported symptom in TSS assessed by MFSAF |  | At Baseline, 3 and 6 months post-FEDR initiation | 
| Frequency of report of domain assessed by Patients' Global Impression of Change (PGIC) |  | At Baseline, 3 and 6 months post-FEDR initiation | 
| Absolute reduction assessed by Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) |  | At Baseline, 3 and 6 months post-FEDR initiation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary Myelofibrosis, Thrombocythemia Myelofibrosis, Fedratinib, Ruxolitinib
Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS

Study Overview
=================
Brief Summary
-----------------
Letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. In 2009, Letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.

Detailed Description
-----------------
Letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. In this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.

Official Title
-----------------
The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment

Conditions
-----------------
Ovarian Hyperstimulation Syndrome

Intervention / Treatment
-----------------
* Drug: letrozole
* Drug: Aspirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infertile women undergoing IVF treatment with more than 25 oocytes collected. Exclusion Criteria: letrozole contraindications,e.g. severe hepatic and renal dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: letrozole<br>letrozole for the first day after ovum picked up at least for 5 days. | Drug: letrozole<br>* letrozole from the day of oocyte retrieval for 5 days<br>* Other names: Femara;|
| Active Comparator: aspirin<br>asprin for the first day after ovum picked up at least for 5 days. | Drug: Aspirin<br>* aspirin from the day of oocyte retrieval for 5 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of early OHSS |  | up to 1 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vascular endothelial growth factor level | vascular endothelial growth factor in pg/ml | up to 1 months | 
| incidence of hydrothorax |  | up to 1 months | 
| incidence of liver dysfunction |  | up to 1 months | 
| incidence of renal dysfunction |  | up to 1 months | 
| incidence of electrolytic imbalance |  | up to 1 months | 
| incidence of hemoconcentration |  | up to 1 months | 
| incidence of elevated WBC |  | up to 1 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
letrozole, ovarian hyperstimulating syndrome
Prevalence of Intracranial Aneurysm in Hong Kong Chinese

Study Overview
=================
Brief Summary
-----------------
Intracranial aneurysm (localized dilatation in weakened blood vessel wall) rupture is a catastrophic disease, with half of the victims died and many of the survivors disabled. There is currently no data in the literature for the Chinese population concerning the prevalence, characteristics (location and size) and risk of harboring an unruptured intracranial aneurysm. In this study, the investigators aim to study the population prevalence and characteristics (location and size) of intracranial aneurysm in Hong Kong Chinese, and its cost-effectiveness. The screening is carried out using magnetic resonance angiography (MRA), with a 3-T magnetic resonance system, which is a well-established non-invasive method for intracranial aneurysm detection.

Detailed Description
-----------------
As charted below.

Official Title
-----------------
Prevalence of Intracranial Aneurysm in Hong Kong Chinese

Conditions
-----------------
Intracranial Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults aged between 21 and 65 years Exclusion Criteria: Contraindications to MRI History of known intracranial pathologies

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hong Kong Chinese<br>Without a history of known intracranial pathologies. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intracranial aneurysm |  | Three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other intracranial pathologies |  | Three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chinese, intracranial aneurysm, magnetic resonance imaging
Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to compare the frequency of suicidality and suicide attempt among HIV patients starting treatment with Efavirenz and with patients starting treatment with other HIV medications.

Official Title
-----------------
The Risk of Suicidality and Suicide Attempt Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens

Conditions
-----------------
HIV Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: At least 6 months of enrollment before first prescription Antiretroviral naive Exclusion Criteria: No diagnosis of HIV on patient record Age < 12 years

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients initiating an Efavirenz<br>Patients initiating an Efavirenz-containing antiretroviral regimen | |
| Patients initiating an Efavirenz-free regimen<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cases of Suicidality, defined as suicidal ideation and suicide attempt |  | Patients will be followed from date of index fill of efavirenz or comparator antiretrovirals until earliest of date of suicidality claim,30th day after the last day of the days supply of the index medication,last day of enrollment or end of study period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of suicide attempt cases, defined as an inpatient or emergency room claim with at least one ICD-9-CM code for suicide attempt |  | Patients will be followed from date of index fill of efavirenz or comparator antiretrovirals until earliest of date of suicidality claim,30th day after the last day of the days supply of the index medication,last day of enrollment or end of study period | 
| Number of suicide attempt cases | Expanded definition, defined as an inpatient of emergency department claim for suicidal attempt or a claim for toxic effects of poisoning, open wound to elbow, wrist or forearm, of asphyxiation plus a diagnosis of psychiatric disorders | Patients will be followed from date of index fill of efavirenz or comparator antiretrovirals until earliest of date of suicidality claim,30th day after the last day of the days supply of the index medication,last day of enrollment or end of study period |
The Influence of Rapid Recovery on Sleep Quality Following Total Knee Replacement Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the influence of rapid recovery on sleep quality following total knee replacement surgery.

Conditions
-----------------
Arthroplasty, Replacement, Knee, Recovery of Function, Arthritis, Rheumatoid

Intervention / Treatment
-----------------
* Behavioral: rapid recovery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary unilateral total knee artropasty; Patients with Knee osteoartritis or Rheumatoid arthritis; Able and willing to provide signed informed consent. Exclusion Criteria: Simultaneously bilateral total knee artropasty or revision case; Surgical History of the knee joint; Knee joint cavity paracentesis in recent 3 months; Stiffness with knee; Blood coagulation disorders; History of deep venous thrombosis; Concomitant medical problems such as uncontrolled hypertention, severe cardiovascular disorder, chronic obstructive pulmonary disease, liver or renal failure allergic to NSAIDs, opioid analgesics, zolpidem sleep apnea, Parkinson disease, dementia, depression use of sedatives or hypnotics inability to comply with polysomnographic measurement

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group<br>rapid recovery | Behavioral: rapid recovery<br>* rapid recovery<br>|
| Controlled group<br>no rapid recovery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC score |  | 1 mounth | 
| GAD-7 |  | 1 mounth | 
| PSQI index |  | 1 mounth | 
| Insomnia severity index |  | 1 mounth | 
| polysomnographic measurement |  | 1 mounth | 
| VAS |  | 1 mounth | 
| Range of motion |  | 1 mounth |
A Prospective Feasibility Study for TAMIS

Study Overview
=================
Brief Summary
-----------------
Most recently, the Transanal Minimally Invasive Surgery (TAMIS) approach combined with single-port technology has allowed that pelvic surgery can be laparoendocopically performed from both its abdominal and perineal aspects.Previously, a strong negative association between medium- and long-term survival and male gender with narrow pelvis have been reported. TAMIS has a significant potantial for improving the quality of the surgical resection of rectal tumors in men with visceral obesity and narrow pelvis. This group of patients have also a high rate of conversion to open surgery. Focusing on improvement in intraoperative conditions and surgical techniques rather than routine conventional procedures may be the way to go concerning favorable short- and long-term outcomes. The selection of adequate surgical approach to the high-risk patients with visceral obesity and a bulky mesentery may prevent or limit the risk for anastomotic leakage and improve oncologic margin clearence. This is a prospective observational feasability study of the TAMIS-procedure.

Official Title
-----------------
A Prospective Quality Assurance Feasibility Study of Laparoscopic Assisted Transanal Minimally Invasive Surgery (TAMIS) for Rectal Cancer

Conditions
-----------------
Rectal Cancer

Intervention / Treatment
-----------------
* Procedure: laparoscopic assisted transanal surgery (TAMIS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: rectal cancer with histological diagnosis tumors located between 10 - 4 cm from the anal verge measured with a rigid rectoscope. suitable for elective resection exclusion criteria: preoperative magnetic resonance imaging (MRI) showing diameter of tumor size >6 cm American Society of Anesthesiologists (ASA) class IV and V anticipated need of intensive care unit (ICU) history of previous major abdominal surgery computer assisted tomography (CT) or MRI evidence of tumor infiltration of adjacent organs obese patient with body mass index >35kg/m2 those, who do not understand the requirements of the protocol pregnancy more than one colorectal tumor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morbidity | Clavien-Dindo | 30-days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | death within 30-days | 30-days | 
| short-term oncological result | cancer-free resection margins | 30-days |
A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain

Official Title
-----------------
An Open Label, Non-comparative, Multicentre Study to Evaluate the Efficacy and Tolerability of Pregabalin in Peripheral Neuropathic Pain

Conditions
-----------------
Neuralgia

Intervention / Treatment
-----------------
* Drug: Pregabalin (Lyrica)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Peripheral neuropathic pain Score of at least 40 mm on the VAS of the SF-MPQ at screening and baseline Completion of at least 4 daily pain diary entries with an average daily pain score of at least 4 over the 7 days prior to baseline Exclusion criteria: (none)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Pregabalin (Lyrica)<br>* Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) visual analog score (VAS) |  | Weeks 1 and 2 and end of treatment | 
| Change from baseline in weekly mean pain scores |  | Weeks 1 and 2 and end of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Euro Quality of Life Questionnaire (EQ-5D) scores |  | End of treatment | 
| Adverse events and laboratory value changes |  | Weeks 1 and 2 and end of treatment | 
| Change from baseline in weekly mean sleep interference score |  | Weeks 1 and 2 and end of treatment | 
| Change from baseline in sensory, affective, and total components of the pain descriptor score and the Present Pain Intensity (PPI) of the SF-MPQ |  | Weeks 1 and 2 and end of treatment | 
| Change from baseline in Patient Global Impression of Change (PGIC) |  | Weeks 1 and 2 and end of treatment | 
| Change from baseline in Clinical Global Impression of Change (CGIC) |  | Weeks 1 and 2 and end of treatment | 
| Change from baseline in pain interference scores on the Brief Pain Inventory (BPI ) Short-Form |  | End of treatment |